Filing Flows › Companies › ResMed › Timeline
ResMed stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−4.8% to $235.30
ResMed (RMD) stock fell 5% over the last 252 sessions, to $235.30. On the way it reported 4 quarters, its insiders filed no open-market trades (10b5-1 plan sales aside) and 7 Form 144 notices of planned sales, and the company filed 3 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Oct 29, 2026 | Earnings | Earnings: beat the EPS estimate by 8.9% | +1.1% (+1.4% vs SPY) | −3.9% (−3.2% vs SPY) | — |
| Oct 23, 2026 | Form 144 | Form 144: Michael J Rider plans to sell $102K | −0.1% (+0.4% vs SPY) | −0.1% (−0.8% vs SPY) | — |
| Oct 7, 2026 | Form 144 | Form 144: Michael Farrell plans to sell $1.1M | +2.4% (+2.6% vs SPY) | +6.3% (+6.4% vs SPY) | +8.6% (+10.2% vs SPY) |
| Sep 8, 2026 | Form 144 | Form 144: Michael Farrell plans to sell $1.1M | −3.2% (−2.7% vs SPY) | −2.4% (−1.2% vs SPY) | −3.4% (−4.8% vs SPY) |
| Sep 2, 2026 | Form 144 | Form 144: Peter C Farrell plans to sell $228K | −0.2% (−0.7% vs SPY) | −5.1% (−5.1% vs SPY) | −4.5% (−5.0% vs SPY) |
| Aug 17, 2026 | 8-K | Change in auditor | −0.2% (+0.5% vs SPY) | +5.6% (+6.8% vs SPY) | +3.8% (+6.2% vs SPY) |
| Aug 7, 2026 | Form 144 | Form 144: Michael Farrell plans to sell $1.0M | −5.2% (−5.8% vs SPY) | +1.5% (+0.3% vs SPY) | +2.5% (+2.3% vs SPY) |
| Aug 6, 2026 | Earnings | Earnings: beat the EPS estimate by 2.0% | −0.3% (−0.2% vs SPY) | +0.9% (+0.5% vs SPY) | +2.6% (+2.1% vs SPY) |
| Aug 5, 2026 | Form 144 | Form 144: Peter C Farrell plans to sell $1.8M | +0.4% (+0.6% vs SPY) | +0.8% (+0.9% vs SPY) | +3.7% (+4.5% vs SPY) |
| Jul 7, 2026 | Form 144 | Form 144: Michael Farrell plans to sell $1.1M | +0.6% (+1.1% vs SPY) | −9.6% (−9.3% vs SPY) | +2.2% (−0.5% vs SPY) |
| Apr 30, 2026 | 8-K | Directors and officers: departures, appointments, pay | −4.2% (−4.5% vs SPY) | −3.3% (−5.1% vs SPY) | −13.4% (−18.8% vs SPY) |
| Apr 30, 2026 | Earnings | Earnings: beat the EPS estimate by 2.1% | +0.9% (−0.1% vs SPY) | −1.1% (−4.2% vs SPY) | −10.3% (−16.5% vs SPY) |
| Jan 29, 2026 | Earnings | Earnings: beat the EPS estimate by 3.2% | 0.0% (+0.2% vs SPY) | +2.0% (+3.4% vs SPY) | −0.3% (+1.0% vs SPY) |
| Nov 20, 2025 | 8-K | Directors and officers: departures, appointments, pay | +2.8% (+1.8% vs SPY) | +4.8% (+0.2% vs SPY) | +1.1% (−4.0% vs SPY) |
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 4.01 Change in auditor | 538 | 0.0% | 49% | −0.1% | ±1.7% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → ResMed: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.